The Experts below are selected from a list of 210 Experts worldwide ranked by ideXlab platform
Asim Ali Khan - One of the best experts on this subject based on the ideXlab platform.
-
Comparative Study to Compare the Efficacy and Safety of a Unani Pharmacopoeial Formulations-UNIM-001+UNIM-003 with Methoxsalen in Cases of Bars (Vitiligo) - A Preliminary Study
2020Co-Authors: Parvez Khan, Radhey Shyam Verma, Sadia Ayub, Sheereen Afza, Jamal Akhtar, Asim Ali KhanAbstract:Background: Vitiligo is a prevalent acquired disorder of skin depigmentation in changeable patterns, differing from small macules with scalloping borders to near total depigmentation of body. The disorder involves nearly 1% to 2% of the world population regardless of race and ethnicity with highest incidence recorded in Indian subcontinent followed by Mexico and Japan. Methodology: A Unani formulation UNIM-001+ UNIM-003 was procured from Central Council for Research in Unani Medicine, New Delhi. Melanocyl Tablet (10mg each) (Methoxsalen) was purchased from Aligarh. Sixty Five patients of Trail group (UNIM-001+ UNIM-003) and sixty seven patients of control group (Comparator group) of 12-50 years of either sex were selected from the lot of patients attending the Out Patient Department (OPD). The patients were instructed to expose themselves to sunlight half an hour to two hours after ingestion of oral drugs. Data were analyzed statistically by one-way analysis of variance (ANOVA) followed by Dennett’s’ test. The values were considered significant when the P-value was found less than 0.05. Result: UNIM-001 Tablet and UNIM-003 topical drug as well as comparator Drug (Melanocyl Tablet (Methoxsalen)) did not induce any negative or unfavorable response. Conclusion: UNIM-001 Tablet and UNIM-003 topical drug as well as comparator Drug (Melanocyl Tablet (Methoxsalen)) Possesses anti-Vitiligo effect. How to cite this article:Khan P, Verma RS, Ayub S, Afza S, Akhtar J, Khan AA. Comparative Study to Compare the Efficacy and Safety of a Unani Pharmacopoeial Formulations-UNIM-001+UNIM-003 with Methoxsalen in Cases of Bars (Vitiligo) - A Preliminary Study. J Adv Res Ayur Yoga Unani Sidd Homeo 2020; 7(3&4): 16-26. DOI: https://doi.org/10.24321/2394.6547.202009
-
comparative study to compare the efficacy and safety of a unani pharmacopoeial formulations unim 001 unim 003 with Methoxsalen in cases of bars vitiligo a preliminary study
Journal of Advanced Research in Ayurveda Yoga Unani Siddha and Homeopathy (ISSN: 2394-6547), 2020Co-Authors: Parvez Khan, Radhey Shyam Verma, Sadia Ayub, Sheereen Afza, Jamal Akhtar, Asim Ali KhanAbstract:Background: Vitiligo is a prevalent acquired disorder of skin depigmentation in changeable patterns, differing from small macules with scalloping borders to near total depigmentation of body. The disorder involves nearly 1% to 2% of the world population regardless of race and ethnicity with highest incidence recorded in Indian subcontinent followed by Mexico and Japan. Methodology: A Unani formulation UNIM-001+ UNIM-003 was procured from Central Council for Research in Unani Medicine, New Delhi. Melanocyl Tablet (10mg each) (Methoxsalen) was purchased from Aligarh. Sixty Five patients of Trail group (UNIM-001+ UNIM-003) and sixty seven patients of control group (Comparator group) of 12-50 years of either sex were selected from the lot of patients attending the Out Patient Department (OPD). The patients were instructed to expose themselves to sunlight half an hour to two hours after ingestion of oral drugs. Data were analyzed statistically by one-way analysis of variance (ANOVA) followed by Dennett’s’ test. The values were considered significant when the P-value was found less than 0.05. Result: UNIM-001 Tablet and UNIM-003 topical drug as well as comparator Drug (Melanocyl Tablet (Methoxsalen)) did not induce any negative or unfavorable response. Conclusion: UNIM-001 Tablet and UNIM-003 topical drug as well as comparator Drug (Melanocyl Tablet (Methoxsalen)) Possesses anti-Vitiligo effect. How to cite this article:Khan P, Verma RS, Ayub S, Afza S, Akhtar J, Khan AA. Comparative Study to Compare the Efficacy and Safety of a Unani Pharmacopoeial Formulations-UNIM-001+UNIM-003 with Methoxsalen in Cases of Bars (Vitiligo) - A Preliminary Study. J Adv Res Ayur Yoga Unani Sidd Homeo 2020; 7(3&4): 16-26. DOI: https://doi.org/10.24321/2394.6547.202009
K. Datta - One of the best experts on this subject based on the ideXlab platform.
-
a sequential anionic 4 2 cycloaddition and thermal 4 2 cycloreversion strategy to furocoumarins a concise synthesis of Methoxsalen
ChemInform, 1995Co-Authors: Dipakranjan Mal, K. V. S. N. Murty, K. DattaAbstract:Abstract The synthesis and utility of unprecedented fluorenofurans 7 and oxa- s -indacenones 8 as key intermediates for synthesis of Methoxsalen 1 is described, illustrating a novel synthetic approach to furocoumarins.
-
A sequential anionic [4 + 2] cycloaddition and thermal [4 + 2] cycloreversion strategy to furocoumarins : A concise synthesis of Methoxsalen
Tetrahedron Letters, 1994Co-Authors: Dipakranjan Mal, K. V. S. N. Murty, K. DattaAbstract:Abstract The synthesis and utility of unprecedented fluorenofurans 7 and oxa- s -indacenones 8 as key intermediates for synthesis of Methoxsalen 1 is described, illustrating a novel synthetic approach to furocoumarins.
Alan I. Cohen - One of the best experts on this subject based on the ideXlab platform.
-
Novel inactivation of the causative fungal pathogen of white-nose syndrome with Methoxsalen plus ultraviolet A or B radiation.
PloS one, 2020Co-Authors: Colin J. Hartman, Joseph C. Mester, Patrick M. Hare, Alan I. CohenAbstract:White-nose syndrome is a fungal disease responsible for the rapid decline of North American bat populations. This study addressed a novel method for inactivating Pseudogymnoascus destructans, the causative agent of WNS, using ultraviolet A (UVA) or B (UVB) radiation in combination with Methoxsalen, a photosensitizer from the furanocoumarin family of compounds. Fungal spore suspensions were diluted in micromolar concentrations of Methoxsalen (50-500 μM), then exposed to fixed doses of UVA radiation (500-5000 mJ/cm2), followed by plating on germination media. These plates were examined for two to four weeks for evidence of spore germination or inactivation, along with resultant growth or inhibition of P. destructans colonies. Pretreatment of fungal spores with low doses of Methoxsalen resulted in a UVA dose-dependent inactivation of the P. destructans spores. All doses of Methoxsalen paired with 500 mJ/cm2 of UVA led to an approximate two-log10 (~99%) reduction in spore viability, and when paired with 1000 mJ/cm2, a four-log10 or greater (>99.99%) reduction in spore viability was observed. Additionally, actively growing P. destructans colonies treated directly with Methoxsalen and either UVA or UVB radiation demonstrated UV dose-dependent inhibition and termination of colony growth. This novel approach of using a photosensitizer in combination with UV radiation to control fungal growth may have broad, practical application in the future.
Rachel F Tyndale - One of the best experts on this subject based on the ideXlab platform.
-
effects of Methoxsalen a cyp2a5 6 inhibitor on nicotine dependence behaviors in mice
Neuropharmacology, 2014Co-Authors: Deniz Bagdas, Pretal P Muldoon, Andy Z X Zhu, Rachel F Tyndale, Imad M DamajAbstract:Metabolism of nicotine to inactive cotinine by hepatic enzyme CYP2A6 is the principal pathway by which active nicotine is removed from circulation. We therefore hypothesized that inhibition of mouse CYP2A5, the ortolog of human CYP2A6, by Methoxsalen (8-methoxypsoralen) alter dependence-related behaviors of nicotine in the mouse. Conditioned place preference (CPP) test was used to assess the appetitive reward-like properties and precipitated nicotine withdrawal to assess physical (somatic and hyperalgesia) and affective (anxiety-related behaviors) measures. The nicotine plasma levels were also measured with or without Methoxsalen pretreatment. Methoxsalen (15 and 30 mg/kg, intraperitoneally) pretreatment enhanced nicotine-induced preference in mice (p<0.05). However, there was a lack of enhancement of nicotine in the CPP test after the highest dose of the CYP-2A5 inhibitor. Similarly to the CPP results, repeated administration of Methoxsalen increased the intensity of mecamylamine-precipitated withdrawal signs. The potentiation of nicotine preference and withdrawal intensity by Methoxsalen was accompanied by significant increase in nicotine plasma levels in mice (p<0.05). Finally, Methoxsalen enhanced the ability of a very low dose of nicotine (0.05 mg/kg) to reverse withdrawal signs in mice undergoing spontaneous withdrawal after chronic nicotine infusion (p<0.05). In conclusion, inhibition of nicotine metabolism by Methoxsalen alters the behavioral effects of nicotine in the mouse. Combining CYP2A6 inhibitors with low dose nicotine replacement therapies may have a beneficial role in smoking cessation because it will decrease the drug elimination rate and maintain plasma and brain nicotine levels.
-
Effects of Methoxsalen, a CYP2A5/6 inhibitor, on nicotine dependence behaviors in mice
Neuropharmacology, 2014Co-Authors: Deniz Bagdas, Pretal P Muldoon, Andy Z X Zhu, Rachel F Tyndale, M. Imad DamajAbstract:Metabolism of nicotine to inactive cotinine by hepatic enzyme CYP2A6 is the principal pathway by which active nicotine is removed from circulation. We therefore hypothesized that inhibition of mouse CYP2A5, the ortolog of human CYP2A6, by Methoxsalen (8-methoxypsoralen) alter dependence-related behaviors of nicotine in the mouse. Conditioned place preference (CPP) test was used to assess the appetitive reward-like properties and precipitated nicotine withdrawal to assess physical (somatic and hyperalgesia) and affective (anxiety-related behaviors) measures. The nicotine plasma levels were also measured with or without Methoxsalen pretreatment. Methoxsalen (15 and 30 mg/kg, intraperitoneally) pretreatment enhanced nicotine-induced preference in mice (p
-
pharmacokinetic and pharmacodynamics studies of nicotine after oral administration in mice effects of Methoxsalen a cyp2a5 6 inhibitor
Nicotine & Tobacco Research, 2014Co-Authors: Shakir D. Alsharari, Rachel F Tyndale, Eric C. K. Siu, Mohamad Imad DamajAbstract:INTRODUCTION The use of novel oral nicotine delivery devices and compositions for human consumption and for animal research studies has been increasing in the last several years. METHODS Studies were undertaken to examine whether the systemic administration of Methoxsalen, an inhibitor of human CYP2A6 and mouse CYP2A5, would modulate nicotine pharmacokinetics and pharmacological effects (antinociception in the tail-flick, and hot-plate tests, and hypothermia) in male ICR mouse after acute oral nicotine administration. RESULTS Administration of intra peritoneal (ip) Methoxsalen significantly increased nicotine's Cmax, prolonged the plasma half-life (fourfold decrease) of nicotine, and increased its area under the curve (AUC) compared with ip vehicle treatment. Methoxsalen pretreatment prolonged the duration of nicotine-induced antinociception and hypothermia (15mg/kg, po) for periods up to 6- and 24-hr postnicotine administration, respectively. Additionally, Methoxsalen potentiated nicotine-induced antinociception and hypothermia as evidenced by leftward shifts in nicotine's dose-response curve. Furthermore, this prolongation of nicotine's effects after Methoxsalen was associated with a parallel prolongation of nicotine plasma levels in mice. These data strongly suggest that variation in the rates of nicotine metabolic inactivation substantially alter pharmacological effects of nicotine given orally. CONCLUSION We have shown that the pharmacological effects of inhibiting nicotine's metabolism after oral administration in mice are profound. Our results suggest that inhibiting nicotine metabolism can be used to dramatically enhance nicotine's bioavailability and its resulting pharmacology, which further supports this inhibitory approach for clinical development of an oral nicotine replacement therapy.
-
Pharmacokinetic and Pharmacodynamics Studies of Nicotine After Oral Administration in Mice: Effects of Methoxsalen, a CYP2A5/6 Inhibitor
Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco, 2013Co-Authors: Shakir D. Alsharari, Rachel F Tyndale, Eric C. K. Siu, Mohamad Imad DamajAbstract:INTRODUCTION The use of novel oral nicotine delivery devices and compositions for human consumption and for animal research studies has been increasing in the last several years. METHODS Studies were undertaken to examine whether the systemic administration of Methoxsalen, an inhibitor of human CYP2A6 and mouse CYP2A5, would modulate nicotine pharmacokinetics and pharmacological effects (antinociception in the tail-flick, and hot-plate tests, and hypothermia) in male ICR mouse after acute oral nicotine administration. RESULTS Administration of intra peritoneal (ip) Methoxsalen significantly increased nicotine's Cmax, prolonged the plasma half-life (fourfold decrease) of nicotine, and increased its area under the curve (AUC) compared with ip vehicle treatment. Methoxsalen pretreatment prolonged the duration of nicotine-induced antinociception and hypothermia (15mg/kg, po) for periods up to 6- and 24-hr postnicotine administration, respectively. Additionally, Methoxsalen potentiated nicotine-induced antinociception and hypothermia as evidenced by leftward shifts in nicotine's dose-response curve. Furthermore, this prolongation of nicotine's effects after Methoxsalen was associated with a parallel prolongation of nicotine plasma levels in mice. These data strongly suggest that variation in the rates of nicotine metabolic inactivation substantially alter pharmacological effects of nicotine given orally. CONCLUSION We have shown that the pharmacological effects of inhibiting nicotine's metabolism after oral administration in mice are profound. Our results suggest that inhibiting nicotine metabolism can be used to dramatically enhance nicotine's bioavailability and its resulting pharmacology, which further supports this inhibitory approach for clinical development of an oral nicotine replacement therapy.
-
EVALUATION OF Methoxsalen, TRANYLCYPROMINE, AND TRYPTAMINE AS SPECIFIC AND SELECTIVE CYP2A6 INHIBITORS IN VITRO
2008Co-Authors: Wenjiang Zhang, Rachel F Tyndale, Tansel Kilicarslan, M. SellersAbstract:CYP2A6 is the principle enzyme metabolizing nicotine to its inactive metabolite cotinine. In this study, the selective probe reactions for each major cytochrome P450 (P450) were used to evaluate the specificity and selectivity of the CYP2A6 inhibitors Methoxsalen, tranylcypromine, and tryptamine in cDNA-expressing and human liver microsomes. Phenacetin O-deethylation (CYP1A2), coumarin 7-hydroxylation (CYP2A6), diclofenac 4�-hydroxylation (CYP2C9), omeprazole 5-hydroxylation (CYP2C19), dextromethorphan O-demethylation (CYP2D6), 7-ethoxy-4-trifluoromethylcoumarin deethylation (CYP2B6), p-nitrophenol hydroxylation (CYP2E1), and omeprazole sulfonation (CYP3A4) were used as index reactions. Apparent K i values for inhibition of P450s ’ (1A2, 2A6, 2B6, 2C9, 2C19, 2D6, 2E1, and 3A4) activities showed that tranylcypromine, Methoxsalen, and tryptamine have high specificity and relative selectivity for CYP2A6. In cDNA-expressing microsomes, tranyl
Parvez Khan - One of the best experts on this subject based on the ideXlab platform.
-
Comparative Study to Compare the Efficacy and Safety of a Unani Pharmacopoeial Formulations-UNIM-001+UNIM-003 with Methoxsalen in Cases of Bars (Vitiligo) - A Preliminary Study
2020Co-Authors: Parvez Khan, Radhey Shyam Verma, Sadia Ayub, Sheereen Afza, Jamal Akhtar, Asim Ali KhanAbstract:Background: Vitiligo is a prevalent acquired disorder of skin depigmentation in changeable patterns, differing from small macules with scalloping borders to near total depigmentation of body. The disorder involves nearly 1% to 2% of the world population regardless of race and ethnicity with highest incidence recorded in Indian subcontinent followed by Mexico and Japan. Methodology: A Unani formulation UNIM-001+ UNIM-003 was procured from Central Council for Research in Unani Medicine, New Delhi. Melanocyl Tablet (10mg each) (Methoxsalen) was purchased from Aligarh. Sixty Five patients of Trail group (UNIM-001+ UNIM-003) and sixty seven patients of control group (Comparator group) of 12-50 years of either sex were selected from the lot of patients attending the Out Patient Department (OPD). The patients were instructed to expose themselves to sunlight half an hour to two hours after ingestion of oral drugs. Data were analyzed statistically by one-way analysis of variance (ANOVA) followed by Dennett’s’ test. The values were considered significant when the P-value was found less than 0.05. Result: UNIM-001 Tablet and UNIM-003 topical drug as well as comparator Drug (Melanocyl Tablet (Methoxsalen)) did not induce any negative or unfavorable response. Conclusion: UNIM-001 Tablet and UNIM-003 topical drug as well as comparator Drug (Melanocyl Tablet (Methoxsalen)) Possesses anti-Vitiligo effect. How to cite this article:Khan P, Verma RS, Ayub S, Afza S, Akhtar J, Khan AA. Comparative Study to Compare the Efficacy and Safety of a Unani Pharmacopoeial Formulations-UNIM-001+UNIM-003 with Methoxsalen in Cases of Bars (Vitiligo) - A Preliminary Study. J Adv Res Ayur Yoga Unani Sidd Homeo 2020; 7(3&4): 16-26. DOI: https://doi.org/10.24321/2394.6547.202009
-
comparative study to compare the efficacy and safety of a unani pharmacopoeial formulations unim 001 unim 003 with Methoxsalen in cases of bars vitiligo a preliminary study
Journal of Advanced Research in Ayurveda Yoga Unani Siddha and Homeopathy (ISSN: 2394-6547), 2020Co-Authors: Parvez Khan, Radhey Shyam Verma, Sadia Ayub, Sheereen Afza, Jamal Akhtar, Asim Ali KhanAbstract:Background: Vitiligo is a prevalent acquired disorder of skin depigmentation in changeable patterns, differing from small macules with scalloping borders to near total depigmentation of body. The disorder involves nearly 1% to 2% of the world population regardless of race and ethnicity with highest incidence recorded in Indian subcontinent followed by Mexico and Japan. Methodology: A Unani formulation UNIM-001+ UNIM-003 was procured from Central Council for Research in Unani Medicine, New Delhi. Melanocyl Tablet (10mg each) (Methoxsalen) was purchased from Aligarh. Sixty Five patients of Trail group (UNIM-001+ UNIM-003) and sixty seven patients of control group (Comparator group) of 12-50 years of either sex were selected from the lot of patients attending the Out Patient Department (OPD). The patients were instructed to expose themselves to sunlight half an hour to two hours after ingestion of oral drugs. Data were analyzed statistically by one-way analysis of variance (ANOVA) followed by Dennett’s’ test. The values were considered significant when the P-value was found less than 0.05. Result: UNIM-001 Tablet and UNIM-003 topical drug as well as comparator Drug (Melanocyl Tablet (Methoxsalen)) did not induce any negative or unfavorable response. Conclusion: UNIM-001 Tablet and UNIM-003 topical drug as well as comparator Drug (Melanocyl Tablet (Methoxsalen)) Possesses anti-Vitiligo effect. How to cite this article:Khan P, Verma RS, Ayub S, Afza S, Akhtar J, Khan AA. Comparative Study to Compare the Efficacy and Safety of a Unani Pharmacopoeial Formulations-UNIM-001+UNIM-003 with Methoxsalen in Cases of Bars (Vitiligo) - A Preliminary Study. J Adv Res Ayur Yoga Unani Sidd Homeo 2020; 7(3&4): 16-26. DOI: https://doi.org/10.24321/2394.6547.202009